Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Biogen

Drug Profile

Interferon beta-1a - Biogen

Alternative Names: Avonex; Avonex Pen; IFN-b-1a; Interferon β-1a

Latest Information Update: 12 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Eisai Co Ltd; Merck & Co; Nektar Therapeutics
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 11 Jan 2019 Merck KGaA completes the phase-II INCREASE trial in Multiple sclerosis in Italy (NCT03387046)
  • 26 Mar 2018 Phase-II clinical trials in Multiple sclerosis (Combination therapy) in Italy (SC) (NCT03387046)
  • 29 Dec 2017 Merck KGaA plans the INCREASE phase II trial for Multiple Sclerosis in Italy in January 2018 , (NCT03387046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top